Smoking has reached an epidemic proportion worldwide and its effect in terms of health-related issues is huge. While smoking prevention and cessation are key to bringing an end to this epidemic, scientific research is needed both to understand smoke-induced pathophysiological mechanisms and to develop novel therapeutic agents to treat patients. The smoking market is also changing, as seen with the introduction of new nicotine delivery devices, such as electronic cigarettes. Their rapid adoption has raised a lot of questions relating to the safety and benefits of these devices, most of which remain incompletely addressed at the present day.
Given the extended time period needed to generate sound scientific evidence, research on tobacco or tobacco-related products requires a joint effort. SCIREQ is proud to be part of these efforts by offering state-of-the-art equipment for basic in vivo and in vitro studies. Particularly well adapted to generate consistent and reproducible exposure environments is the inExpose system, a versatile and programmable exposure system that can be configured with several smoke and vape generating devices. The impact on the respiratory system can then be assessed using invasive and non-invasive lung function measurement techniques. Sitting at the forefront, the flexiVent system offers a variety of lung function measurements to address specific questions or gain novel insights. These accurate and detailed measurements can be complemented by the non-invasive barometric monitoring of the ventilation profile or disease symptoms (e.g. cough) throughout a study, which can involve repeated exposure sessions over several months. Finally, any direct effect on either airway or vascular smooth muscle can also be evaluated in absence of external influences using tissue baths for an overall meaningful and far-reaching assessment.
Learn more about ENDS exposure solutions and the development of translatable pre-clinical animal models here.